PeptidePlaza
The Free Peptide Reference

Ceruletide

From PeptidePlaza, the free peptide reference · Entry #1062 · Nootropic · Sources fetched 2026-09-11 · Editorial standards

Ceruletide (also known as Caerulein, Cerulein, Ceruletida, Ceruletidum) is a nootropic research peptide. Ceruletide is a synthetic peptide and cholecystokinin (CCK) agonist, approved by the FDA for diagnostic and therapeutic uses.

Ceruletide, also known as Caerulein, is a decapeptide that functions as an agonist of cholecystokinin (CCK) receptors. It mimics the effects of the natural hormone cholecystokinin and the amphibian skin peptide caerulein. Ceruletide is FDA-approved and has been studied for its neuropharmacological properties and its potential as an analgesic drug. Research has also explored its use in conditions such as postoperative ileus, neuroleptic-induced tardive dyskinesia, and schizophrenia. Its regulatory approval dates back to 1982.

1 Chemical and physical properties

CAS number17650-98-5
Molar mass1352.4 g/mol
Purity (typical)Not independently verified
Storage−20 °C, lyophilised powder, desiccated
SolubilitySterile water / bacteriostatic water

1.1 Amino acid sequence

Pyr-Gln-Asp-Tyr(SO3H)-Thr-Gly-Trp-Met-Asp-Phe-NH2

2 Research studies (8)

  1. Postoperative ileus: progress towards effective management
    Drugs (2002) · Review
  2. Caerulein and its analogues: neuropharmacological properties
    Peptides (1985) · Review
  3. Miscellaneous treatments for neuroleptic-induced tardive dyskinesia
    The Cochrane database of systematic reviews (2003) · Systematic Review
  4. Rediscovery of Ceruletide, a CCK Agonist, as an Analgesic Drug
    Journal of pain research (2020) · Review
  5. Ceruletide for schizophrenia: a review
    Psychopharmacology bulletin (1986) · Review
  6. β-elemene directly targets IL-17RA in macrophages to inhibit inflammation and attenuate acute pancreatitis
    Phytomedicine : international journal of phytotherapy and phytopharmacology (2026)
  7. The metalloproteinase ADAM17 promotes acute lung inflammatory responses during pancreatitis
    British journal of pharmacology (2026)
  8. Current topics in tardive dyskinesia in Japan
    Psychiatry and clinical neurosciences (1995) · Review

3 Safety and risk profile

3.1 Regulatory status

Ceruletide is currently classified as FDA approved. Approval applies to specific clinical indications and dosing; research-grade material is not the approved product.

Safety data disclaimer. Safety assessments are based on published literature and are for educational reference only. Clinical evidence varies significantly between peptides. Always consult primary research and current regulatory guidance.

4 Frequently asked questions

What is Ceruletide?
Ceruletide is a synthetic decapeptide that acts as an agonist for cholecystokinin (CCK) receptors. It is also known as Caerulein and mimics the actions of both cholecystokinin and the amphibian peptide caerulein.
How does Ceruletide work?
Ceruletide works by binding to and activating cholecystokinin (CCK) receptors as an agonist. This action mimics the physiological effects of the natural hormone cholecystokinin in the body.
Is Ceruletide FDA approved?
Yes, Ceruletide is an FDA-approved compound. It received its first approval in 1982 for various diagnostic and therapeutic applications.
What is Ceruletide studied for?
Ceruletide has been studied for its neuropharmacological properties and as a potential analgesic. Research has also investigated its role in conditions such as postoperative ileus, neuroleptic-induced tardive dyskinesia, and schizophrenia.

5 References

  1. Ceruletide — compound summary PubChem. View source
  2. Ceruletide — molecule record ChEMBL. View source
  3. Ceruletide — published literature (296 records) PubMed. View source

Related compounds

Entries that share a target, a mechanism, or a research area with Ceruletide.

Substance Pnootropic

Also nootropic

Substance P, also known as Neurokinin P, is an endogenous human peptide and a member of the tachykinin family.

Vasoactive Intestinal Peptidenootropic

Also nootropic

Vasoactive Intestinal Peptide (VIP) is a neuropeptide that activates VIP receptor 1 (VPR1) and VIP receptor 2 (VPR2), which are G protein-coupled receptors.

Oxytocinapproved

Also nootropic

A nine-amino-acid neuropeptide hormone best known for childbirth and lactation, now studied extensively for social bonding, stress regulation, wound healing, and metabolic effects via intranasal delivery.

PT-141approved

Also nootropic

A cyclic heptapeptide melanocortin receptor agonist and active metabolite of Melanotan II. Unlike peripheral vasodilators, PT-141 acts centrally via the CNS to modulate arousal and food intake pathways.

Melanotan IInootropic

Also nootropic

A potent cyclic analog of α-MSH that activates melanocortin receptors broadly. Studied for UV-independent melanogenesis, appetite suppression, and as the parent compound of PT-141 (Bremelanotide).

Eptifibatideapproved

Also nootropic

Eptifibatide is an integrin alpha-IIb/beta-3 inhibitor used to decrease the rate of death or myocardial infarction in patients with acute coronary syndrome and those undergoing percutaneous coronary intervention.

6 See also

For research reference only. Not medical advice. Peptides may be regulated or restricted in your jurisdiction. Entry validated by the PeptidePlaza Biomedical Research Desk; see editorial standards.